Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Tema Oncology ETF (NASDAQ:CANC) through any online brokerage.
There are no as such competitors for Tema Oncology ETF.
There is no analysis for Tema Oncology ETF to provide a consensus price target.
The stock price for Tema Oncology ETF (NASDAQ: CANC) is $45 last updated September 3, 2026 at 6:48 PM EDT.
There are no upcoming dividends for Tema Oncology ETF.
Tema Oncology ETF does not have any upcoming earnings scheduled.
There is no upcoming split for Tema Oncology ETF.
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Large Cap Blend |
| Fund Inception | Aug 15, 2023 |
| Managers | Yuri Khodjamirian Maurits Pot David Song |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
| Symbol | Name | Share % |
|---|---|---|
| RVMD | Revolution Medicines I... | 6.54% |
| LLY | Eli Lilly & Co. | 5.39% |
| FF | Roche Holdings Ag | 4.26% |
| COGT | Cogent Biosciences Inc | 4.96% |
| MRK | Merck & Co. Inc. | 3.22% |
| BMY | Bristol-Myers Squibb C... | 3.49% |
| NOVN | Novartis Ag | 3.79% |
| ABBV | Abbvie Inc. | 3.31% |
| JNJ | Johnson & Johnson - Co... | 3.11% |
| BGNE | Beigene, Ltd. Adr | 3.22% |
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
